

Mehdi Farokhnia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7613421/publications.pdf>

Version: 2024-02-01

56
papers

2,233
citations

201385

27
h-index

233125

45
g-index

58
all docs

58
docs citations

58
times ranked

2671
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | A closer look at alcohol-induced changes in the ghrelin system: novel insights from preclinical and clinical data. <i>Addiction Biology</i> , 2022, 27, e13033. | 1.4 | 17 |
| 2 | Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review. <i>Pharmacological Reviews</i> , 2022, 74, 119-140. | 7.1 | 72 |
| 3 | Harm reduction and abstinence-based models for treatment of substance use disorders during the COVID-19 pandemic: a global perspective. <i>BJPsych International</i> , 2022, 19, 66-69. | 0.8 | 9 |
| 4 | The Mineralocorticoid Receptor: An Emerging Pharmacotherapeutic Target for Alcohol Use Disorder?. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1832-1834. | 1.7 | 3 |
| 5 | A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation. <i>Molecular Psychiatry</i> , 2021, 26, 545-555. | 4.1 | 21 |
| 6 | Neuroendocrine Response to Exogenous Ghrelin Administration, Combined With Alcohol, in Heavy-Drinking Individuals: Findings From a Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 464-476. | 1.0 | 11 |
| 7 | Leptin Gene and Leptin Receptor Gene Polymorphisms in Alcohol Use Disorder: Findings Related to Psychopathology. <i>Frontiers in Psychiatry</i> , 2021, 12, 723059. | 1.3 | 3 |
| 8 | Effect of oral alcohol administration on plasma cytokine concentrations in heavy drinking individuals. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108771. | 1.6 | 8 |
| 9 | Effectiveness of spironolactone dispensation in reducing weekly alcohol use: a retrospective high-dimensional propensity score-matched cohort study. <i>Neuropsychopharmacology</i> , 2021, 46, 2140-2147. | 2.8 | 9 |
| 10 | Effect of intravenous ghrelin administration, combined with alcohol, on circulating metabolome in heavy drinking individuals with alcohol use disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 2207-2216. | 1.4 | 3 |
| 11 | A population-based investigation of the association between alcohol intake and serum total ghrelin concentrations among cigarette-smoking, non-alcohol-dependent male individuals. <i>Drug and Alcohol Dependence</i> , 2021, 226, 108835. | 1.6 | 4 |
| 12 | Patterns of reduced use and abstinence in multi-site randomized controlled trials of pharmacotherapies for cocaine and methamphetamine use disorders. <i>Drug and Alcohol Dependence</i> , 2021, 226, 108904. | 1.6 | 2 |
| 13 | OUP accepted manuscript. <i>Alcohol and Alcoholism</i> , 2021, , . | 0.9 | 8 |
| 14 | Blood Biomarkers of Alcohol Use: A Scoping Review. <i>Current Addiction Reports</i> , 2021, 8, 500-508. | 1.6 | 9 |
| 15 | The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study. <i>Molecular Psychiatry</i> , 2020, 25, 461-475. | 4.1 | 90 |
| 16 | Endocrine effects of the novel ghrelin receptor inverse agonist PF-5190457: Results from a placebo-controlled human laboratory alcohol co-administration study in heavy drinkers. <i>Neuropharmacology</i> , 2020, 170, 107788. | 2.0 | 19 |
| 17 | Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats. <i>Frontiers in Neuroscience</i> , 2020, 14, 599646. | 1.4 | 30 |
| 18 | Investigating the link between serum concentrations of brain-derived neurotrophic factor and behavioral measures in anxious alcohol-dependent individuals. <i>Alcohol</i> , 2020, 89, 75-83. | 0.8 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study. <i>Translational Psychiatry</i> , 2020, 10, 71. | 2.4 | 48 |
| 20 | Effects of exogenous ghrelin administration and ghrelin receptor blockade, in combination with alcohol, on peripheral inflammatory markers in heavy-drinking individuals: Results from two human laboratory studies. <i>Brain Research</i> , 2020, 1740, 146851. | 1.1 | 13 |
| 21 | The Promise of Neuroimmune Targets for Treating Drug Addiction and Other Psychiatric Disorders: Granulocyte-Colony Stimulating Factor Exemplification. <i>Frontiers in Psychiatry</i> , 2020, 11, 220. | 1.3 | 5 |
| 22 | Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: Results from a double-blind, placebo-controlled human laboratory study. <i>Neuropharmacology</i> , 2019, 158, 107711. | 2.0 | 11 |
| 23 | Substance Use among Economically Disadvantaged African American Older Adults; Objective and Subjective Socioeconomic Status. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 1826. | 1.2 | 40 |
| 24 | Ghrelin: From a gut hormone to a potential therapeutic target for alcohol use disorder. <i>Physiology and Behavior</i> , 2019, 204, 49-57. | 1.0 | 80 |
| 25 | Education Attainment and Alcohol Binge Drinking: Diminished Returns of Hispanics in Los Angeles. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2019, 9, 9. | 1.0 | 118 |
| 26 | Prospects for pharmacotherapies to treat alcohol use disorder. <i>Current Opinion in Psychiatry</i> , 2019, 32, 255-265. | 3.1 | 25 |
| 27 | Neuroendocrine response to GABA-B receptor agonism in alcohol-dependent individuals: Results from a combined outpatient and human laboratory experiment. <i>Neuropharmacology</i> , 2018, 137, 230-239. | 2.0 | 8 |
| 28 | Impulsive Personality Traits Mediate the Relationship Between Adult Attention-Deficit/Hyperactivity Symptoms and Alcohol Dependence Severity. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 173-183. | 1.4 | 20 |
| 29 | Exogenous ghrelin administration increases alcohol self-administration and modulates brain functional activity in heavy-drinking alcohol-dependent individuals. <i>Molecular Psychiatry</i> , 2018, 23, 2029-2038. | 4.1 | 82 |
| 30 | Identifying and Characterizing Subpopulations of Heavy Alcohol Drinkers Via a Sucrose Preference Test: A Sweet Road to a Better Phenotypic Characterization?. <i>Alcohol and Alcoholism</i> , 2018, 53, 560-569. | 0.9 | 10 |
| 31 | Pharmacological manipulation of the ghrelin system and alcohol hangover symptoms in heavy drinking individuals: Is there a link?. <i>Pharmacology Biochemistry and Behavior</i> , 2018, 172, 39-49. | 1.3 | 19 |
| 32 | Extracellular esterase activity as an indicator of endoplasmic reticulum calcium depletion. <i>Biomarkers</i> , 2018, 23, 756-765. | 0.9 | 15 |
| 33 | The Validity of the Montgomery-Asberg Depression Rating Scale in an Inpatient Sample with Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1220-1227. | 1.4 | 10 |
| 34 | The Microbiota, the Gut and the Brain in Eating and Alcohol Use Disorders: A <i>“MÃ©nage Ã Trois”</i> ?. <i>Alcohol and Alcoholism</i> , 2017, 52, 403-413. | 0.9 | 66 |
| 35 | Commentary on Schmitz <i>et al</i> . (2017): Advancing medication development for addiction- <i>“behavioral and neuroimaging outcomes as indirect biomarkers of target engagement.</i> <i>Addiction</i> , 2017, 112, 1869-1870. | 1.7 | 1 |
| 36 | The Role of the Ghrelin System in Drug Addiction. <i>International Review of Neurobiology</i> , 2017, 136, 89-119. | 0.9 | 74 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. <i>Human Psychopharmacology</i> , 2016, 31, 103-112. | 0.7 | 41 |
| 38 | Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial. <i>Bipolar Disorders</i> , 2015, 17, 606-614. | 1.1 | 78 |
| 39 | Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial. <i>Journal of Psychopharmacology</i> , 2015, 29, 575-581. | 2.0 | 60 |
| 40 | PIOGLITAZONE ADJUNCTIVE THERAPY FOR DEPRESSIVE EPISODE OF BIPOLAR DISORDER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. <i>Depression and Anxiety</i> , 2015, 32, 167-173. | 2.0 | 94 |
| 41 | A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism. <i>Psychiatry Research</i> , 2015, 229, 181-187. | 1.7 | 53 |
| 42 | N-Acetylcysteine as an Adjunctive Therapy to Risperidone for Treatment of Irritability in Autism. <i>Clinical Neuropharmacology</i> , 2015, 38, 11-17. | 0.2 | 86 |
| 43 | Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial. <i>Journal of Psychopharmacology</i> , 2014, 28, 677-685. | 2.0 | 62 |
| 44 | A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. <i>Psychopharmacology</i> , 2014, 231, 533-542. | 1.5 | 34 |
| 45 | Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. <i>Psychiatry Research</i> , 2014, 215, 540-546. | 1.7 | 87 |
| 46 | A randomized, double-blind, clinical trial comparing the efficacy and safety of <i>Crocus sativus</i> L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. <i>Journal of Affective Disorders</i> , 2014, 155, 216-222. | 2.0 | 111 |
| 47 | Comparing the efficacy and safety of <i>Crocus sativus</i> L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial. <i>Human Psychopharmacology</i> , 2014, 29, 351-359. | 0.7 | 114 |
| 48 | l-lysine as an adjunct to risperidone in patients with chronic schizophrenia: A double-blind, placebo-controlled, randomized trial. <i>Journal of Psychiatric Research</i> , 2014, 59, 125-131. | 1.5 | 30 |
| 49 | Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: A randomized, double-blind, placebo-controlled, clinical trial. <i>European Neuropsychopharmacology</i> , 2014, 24, 846-855. | 0.3 | 17 |
| 50 | A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. <i>Psychopharmacology</i> , 2013, 228, 595-602. | 1.5 | 36 |
| 51 | Riluzole as an Adjunctive Therapy to Risperidone for the Treatment of Irritability in Children with Autistic Disorder: A Double-Blind, Placebo-Controlled, Randomized Trial. <i>Paediatric Drugs</i> , 2013, 15, 505-514. | 1.3 | 47 |
| 52 | Aspirin for treatment of lithium-associated sexual dysfunction in men: randomized double-blind placebo-controlled study. <i>Bipolar Disorders</i> , 2013, 15, 650-656. | 1.1 | 47 |
| 53 | N-Acetylcysteine as an Adjunct to Risperidone for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia. <i>Clinical Neuropharmacology</i> , 2013, 36, 185-192. | 0.2 | 121 |
| 54 | Double-Blind, Placebo-Controlled Trial of Risperidone Plus Amantadine in Children With Autism. <i>Clinical Neuropharmacology</i> , 2013, 36, 179-184. | 0.2 | 44 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Cardiovascular considerations in antidepressant therapy: an evidence-based review. The Journal of Tehran Heart Center, 2013, 8, 169-76. | 0.3 | 21 |
| 56 | Oral Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder. Journal of Clinical Psychiatry, 2012, 73, 1428-1433. | 1.1 | 81 |